share_log

Redhill Biopharma | CORRESP: CORRESP

Redhill Biopharma | CORRESP: CORRESP

Redhill Biopharma | CORRESP：信函
SEC announcement ·  02/15 12:59
Moomoo AI 已提取核心訊息
RedHill Biopharma Ltd., an Israel-based pharmaceutical company, has formally requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form F-1. The request, filed on February 15, 2024, seeks to advance the effective date to 4:30 p.m. Eastern Time on the same day, or as soon as possible thereafter. This action follows the initial filing of the Registration Statement on February 9, 2024, under file number 333-276979. RedHill Biopharma has designated its counsel, Haynes and Boone, LLP, to receive notification of the Registration Statement's effectiveness via telephone, with a follow-up confirmation in writing.
RedHill Biopharma Ltd., an Israel-based pharmaceutical company, has formally requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form F-1. The request, filed on February 15, 2024, seeks to advance the effective date to 4:30 p.m. Eastern Time on the same day, or as soon as possible thereafter. This action follows the initial filing of the Registration Statement on February 9, 2024, under file number 333-276979. RedHill Biopharma has designated its counsel, Haynes and Boone, LLP, to receive notification of the Registration Statement's effectiveness via telephone, with a follow-up confirmation in writing.
總部位於以色列的製藥公司RedHill Biopharma Ltd. 已正式要求美國證券交易委員會（SEC）加快其F-1表格註冊聲明的生效日期。該請求於2024年2月15日提出，旨在將生效日期提前至美國東部時間當天下午 4:30，或之後儘快提前。該行動是在2024年2月9日首次提交註冊聲明之後採取的，文件編號爲333-276979。RedHill Biopharma已指定其律師Haynes and Boone, LLP通過電話接收註冊聲明的生效通知，並附上後續書面確認。
總部位於以色列的製藥公司RedHill Biopharma Ltd. 已正式要求美國證券交易委員會（SEC）加快其F-1表格註冊聲明的生效日期。該請求於2024年2月15日提出，旨在將生效日期提前至美國東部時間當天下午 4:30，或之後儘快提前。該行動是在2024年2月9日首次提交註冊聲明之後採取的，文件編號爲333-276979。RedHill Biopharma已指定其律師Haynes and Boone, LLP通過電話接收註冊聲明的生效通知，並附上後續書面確認。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息